Our research activities are tightly integrated with an advanced genomics facility platform providing cutting - edge technologies for high - throughput analysis and next
generation genomic approaches and are supported by the CRS4 leading High Performance Computing centre.
Not exact matches
This «next -
generation sampling»
approach of pairing
genomics with large - scale herbarium sampling showed considerable promise as sufficient data were obtained for 98 % of samples, data which identified genetic groups that frequently matched morphologically defined species.
Information gained from this work will serve to enhance the clinical usefulness of findings from
genomic sequencing (for example, next -
generation sequencing or comprehensive
genomic profiling), determine therapeutic
approaches based on
genomic findings, aid in the development of clinical trials and related options, and provide supportive rationale for exploring new therapies.
MELGEN will explore emergent new techniques, for example the Sanger Institute (GRL) and ServiceXS will explore new
approaches to
genomic data
generation from such samples and from fresh tumour and, critically, with other participant groups develop new statistical / bioinformatic
approaches to data analysis.
As part of an ongoing functional
genomic screening
approach, we have been using microarray analysis and next
generation sequencing to identify mouse genes that are specifically expressed in meiosis, and are likely involved in aspects of chromosome biology that are required for meiotic ploidy reduction.